Kahn Brothers Group Inc. Makes New $8.30 Million Investment in GSK PLC Sponsored ADR $GSK

Kahn Brothers Group Inc. acquired a new stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm acquired 158,438 shares of the pharmaceutical company's stock, valued at approximately $8,305,000. GSK comprises 0.0% of Kahn Brothers Group Inc.'s holdings, making the stock its 28th largest position.

Other hedge funds have also recently modified their holdings of the company. Brighton Jones LLC purchased a new stake in shares of GSK during the fourth quarter valued at approximately $528,000. AQR Capital Management LLC boosted its position in GSK by 84.4% in the first quarter. AQR Capital Management LLC now owns 40,239 shares of the pharmaceutical company's stock worth $1,559,000 after purchasing an additional 18,420 shares during the last quarter. Empowered Funds LLC boosted its position in GSK by 2.1% in the first quarter. Empowered Funds LLC now owns 79,174 shares of the pharmaceutical company's stock worth $3,067,000 after purchasing an additional 1,598 shares during the last quarter. Rhumbline Advisers grew its stake in GSK by 20.7% in the 2nd quarter. Rhumbline Advisers now owns 22,209 shares of the pharmaceutical company's stock valued at $853,000 after purchasing an additional 3,806 shares during the period. Finally, Gabelli Funds LLC increased its position in shares of GSK by 17.8% during the 2nd quarter. Gabelli Funds LLC now owns 7,960 shares of the pharmaceutical company's stock valued at $306,000 after purchasing an additional 1,200 shares during the last quarter. Institutional investors own 15.74% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on GSK shares. Morgan Stanley reiterated an "underweight" rating on shares of GSK in a research note on Tuesday. Wall Street Zen downgraded shares of GSK from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. Royal Bank Of Canada reaffirmed an "outperform" rating on shares of GSK in a research report on Tuesday, June 9th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of GSK in a research note on Thursday, July 30th. Finally, Jefferies Financial Group raised shares of GSK to a "strong-buy" rating in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $53.00.

GSK Stock Down 2.2%

GSK stock opened at $50.27 on Friday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.52 and a current ratio of 0.82. The company has a market capitalization of $101.69 billion, a price-to-earnings ratio of 15.72, a PEG ratio of 2.97 and a beta of 0.36. GSK PLC Sponsored ADR has a fifty-two week low of $38.63 and a fifty-two week high of $61.69. The stock has a fifty day moving average of $51.82 and a 200-day moving average of $53.51.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.27 by $0.09. The business had revenue of $11.14 billion for the quarter, compared to analysts' expectations of $11.02 billion. GSK had a return on equity of 43.23% and a net margin of 14.56%.The firm's quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.47 EPS. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, equities research analysts predict that GSK PLC Sponsored ADR will post 4.8 earnings per share for the current year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 8th. Stockholders of record on Friday, August 14th will be given a $0.4515 dividend. This represents a $1.81 annualized dividend and a dividend yield of 3.6%. This is an increase from GSK's previous quarterly dividend of $0.44. The ex-dividend date of this dividend is Friday, August 14th. GSK's payout ratio is presently 55.63%.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK's core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source